These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8151008)

  • 1. Fluvoxamine treatment of body dysmorphic disorder.
    Hollander E; Cohen L; Simeon D; Rosen J; DeCaria C; Stein DJ
    J Clin Psychopharmacol; 1994 Feb; 14(1):75-7. PubMed ID: 8151008
    [No Abstract]   [Full Text] [Related]  

  • 2. Near-fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine.
    O'Sullivan RL; Phillips KA; Keuthen NJ; Wilhelm S
    Psychosomatics; 1999; 40(1):79-81. PubMed ID: 9989126
    [No Abstract]   [Full Text] [Related]  

  • 3. What is the optimal approach to the pharmacological management of obsessive-compulsive disorder?
    Ravindran AV
    J Psychiatry Neurosci; 1998 Mar; 23(2):136. PubMed ID: 9549253
    [No Abstract]   [Full Text] [Related]  

  • 4. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
    McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
    J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulpiride addition in a case of fluvoxamine-refractory obsessive-compulsive disorder without comorbid psychopathology.
    Sevincok L; Uslu A; Kaynak H; Dereboy F
    J Psychiatry Neurosci; 2000 Mar; 25(2):185. PubMed ID: 10740992
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder.
    Trabert W; Hohagen F; Winkelmann G; Berger M
    Pharmacopsychiatry; 1995 May; 28(3):95-7. PubMed ID: 7568372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin selectivity for obsessive compulsive and panic disorders.
    Montgomery SA; Bullock T; Fineberg N
    J Psychiatry Neurosci; 1991 Jul; 16(2 Suppl 1):30-5. PubMed ID: 1931935
    [No Abstract]   [Full Text] [Related]  

  • 9. When fluvoxamine treats only depression and clomipramine treats only obsessive-compulsive disorder--combine them?
    Schaller JL; Behar D; Chamberlain T
    J Neuropsychiatry Clin Neurosci; 1998; 10(1):111-3. PubMed ID: 9547477
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment.
    Cavedini P; Erzegovesi S; Ronchi P; Bellodi L
    Eur Neuropsychopharmacol; 1997 Feb; 7(1):45-9. PubMed ID: 9088884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder.
    Volkers AC; Tulen JH; van den Broek WW; Bruyn JA; Passchier J; Pepplinkhuizen L
    Pharmacopsychiatry; 2004 Jan; 37(1):18-25. PubMed ID: 14750044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder.
    Nakaaki S; Murata Y; Furukawa TA
    Psychiatry Clin Neurosci; 2008 Jun; 62(3):370. PubMed ID: 18588607
    [No Abstract]   [Full Text] [Related]  

  • 13. Fluvoxamine for obsessive-compulsive disorder.
    Med Lett Drugs Ther; 1995 Feb; 37(942):13-4. PubMed ID: 7845314
    [No Abstract]   [Full Text] [Related]  

  • 14. Body dysmorphic disorder.
    Myers WA
    Am J Psychiatry; 1992 May; 149(5):718; author reply 719. PubMed ID: 1575279
    [No Abstract]   [Full Text] [Related]  

  • 15. Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage.
    Lenzi A; Raffaelli S; Marazziti D
    Pharmacopsychiatry; 1993 May; 26(3):100-1. PubMed ID: 8415895
    [No Abstract]   [Full Text] [Related]  

  • 16. Body dysmorphic disorder.
    Castelnuovo-Tedesco P
    Am J Psychiatry; 1992 May; 149(5):718; author reply 719. PubMed ID: 1575278
    [No Abstract]   [Full Text] [Related]  

  • 17. Insight in obsessive compulsive disorder and body dysmorphic disorder.
    Eisen JL; Phillips KA; Coles ME; Rasmussen SA
    Compr Psychiatry; 2004; 45(1):10-5. PubMed ID: 14671731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report.
    Ueda N; Terao T; Ohmori O; Nakamura J
    Hum Psychopharmacol; 2003 Aug; 18(6):477-8. PubMed ID: 12923827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perceived teasing experiences in body dysmorphic disorder.
    Buhlmann U; Cook LM; Fama JM; Wilhelm S
    Body Image; 2007 Dec; 4(4):381-5. PubMed ID: 18089284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluvoxamine-associated mania/hypomania in patients with obsessive-compulsive disorder.
    Jefferson JW; Greist JH; Perse TL; Rosenfeld R
    J Clin Psychopharmacol; 1991 Dec; 11(6):391-2. PubMed ID: 1770160
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.